RCT | Durvalumab with or without Tremelimumab plus chemotherapy for metastatic non–small-cell lung cancer.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study – Journal of Clinical Oncology

Commentary: Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC – Cancer Therapy Advisor

Commentary on Twitter

? POSEIDON: 1L tremelimumab + durvalumab + chemotherapy significantly improve progression-free and overall survival in stage IV non small cell #LungCancer ? https://t.co/d6causVZ4u #JCO #ImmunoOnc #Immunotherapy #LCSM @MLJohnsonMD2 #NSCLC pic.twitter.com/aIkCwSAwFe

— Journal of Clinical Oncology (@JCO_ASCO) December 3, 2022